4//SEC Filing
Raptor Pharmaceutical Corp 4
Accession 0001140361-16-083651
CIK 0001070698operating
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 4:40 PM ET
Size
7.8 KB
Accession
0001140361-16-083651
Insider Transaction Report
Form 4
Smith Michael P
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2016-10-25−84,751→ 0 totalExercise: $3.74Exp: 2026-02-09→ Common Stock (84,751 underlying) - Disposition to Issuer
Common Stock
2016-10-25$9.00/sh−22,607$203,463→ 0 total
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger dated as of September 12, 2016, by and among Raptor Pharmaceutical Corp., Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (the "Merger Agreement"), on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
- [F2]Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Documents
Issuer
Raptor Pharmaceutical Corp
CIK 0001070698
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001070698
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 4:40 PM ET
- Size
- 7.8 KB